MedTrace Logo

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

NCT06142357 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2025-12-24

No results posted yet for this study

Summary

Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.

Conditions

  • Moderate-to-severe Plaque Psoriasis

Interventions

OTHER

Secukinumab

There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-29
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06142357 on ClinicalTrials.gov